{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'H', 'HORIZON', 'P', 'H A R M', 'A', 'CLINICAL STUDY PROTOCOL', 'FOR TEPROTUMUMAB (HZN-001)', 'IND: 112952', 'Protocol Number: HZNP-TEP-301', 'EudraCT No.: 2017-002763-18', 'A Phase 3, Randomized, Double-Masked Placebo-Controlled, Parallel-Group,', 'Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in', 'Subjects with Active Thyroid Eye Disease', 'Short Title: SPTIC', \"Treatment of Graves' Orbitopathy to Reduce Proptosis with Teprotumumab Infusions in a\", 'Randomized, Placebo-Controlled, Clinical Study', 'Date: 31 January 2019', 'Version 4.0, incorporating Amendment 3', 'Sponsor:', 'Horizon Pharma USA, Inc.', '150 S. Saunders Road', 'Lake Forest, IL 60045', 'This protocol is the confidential information of Horizon Pharma USA, Inc. and is intended solely for the guidance of the clinical', 'investigation. This protocol may not be disclosed to parties not associated with the clinical investigation or used for any purpose without the', 'prior written consent of Horizon Pharma USA, Inc.', 'CONFIDENTIAL', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 1 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'PROTOCOL', '1', 'TITLE PAGE', 'Study Title: A Phase 3, Randomized, Double-Masked,', 'Placebo-Controlled, Parallel-Group, Multicenter', 'Study Evaluating Teprotumumab (HZN-001)', 'Treatment in Subjects with Active Thyroid Eye', 'Disease (OPTIC)', 'Protocol Number:', 'HZNP-TEP-301', 'Version: 4.0 incorporating Amendment 3', 'Investigational Product: Teprotumumab (HZN-001)', 'Indication:', 'Thyroid Eye Disease (TED)', \"(also called Graves' Ophthalmopathy or\", 'Orbitopathy [GO] and Thyroid-Associated', 'Ophthalmopathy [TAO]).', 'Sponsor: Horizon Pharma USA, Inc.', '150 S. Saunders Road', 'Lake Forest, IL 60045', 'Development Phase:', '3', \"Sponsor's Responsible Medical Officer:\", 'Horizon Pharma USA, Inc.', '150 S. Saunders Road', 'Lake Forest, IL 60045', 'Sponsor Signatory:', 'Horizon Pharma USA, Inc.', 'Approval Date: 31 January 2019', 'CONTACT IN THE EVENT OF AN EMERGENCY', 'Any death, life threatening event, or other Serious Adverse Event experienced by a subject', 'during the course of the study, whether or not judged drug-related, must be reported within', '24 hours of knowledge of the event by entering the information into the electronic case report', 'form (eCRF). If unable to access the eCRF, the event must be reported by submitting the', 'completed Serious Adverse Event Form via email or fax to the contact numbers provided below.', 'Fax:', 'Email:', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 2 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Protocol: HZNP-TEP-301', 'Date: 31 January 2019', 'Version 4.0, incorporating Amendment 3', 'SPONSOR SIGNATURE PAGE', 'Protocol Number:', 'HZNP-TEP-301', 'Version:', '4.0, incorporating Amendment 3', 'Protocol Title:', 'A Phase 3, Randomized, Double-Masked, Placebo-Controlled,', 'Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001)', 'Treatment in Subjects with Active Thyroid Eye Disease (OPTIC)', 'Version Date:', '31 Januery 2019', 'Approved by:', '06FEB2019', 'Date', 'Horizon Pharma USANInc', '2-6-19', 'Date', '2.2.19', 'Date', '06 FEB2019', 'Date', 'Feb 6,2019', 'Date', 'Horizon the.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 3 of 117']\n\n###\n\n", "completion": "END"}